Introducing Off Protocol: Lindus Health’s New Clinical Trials Podcast

Sep 30, 2025

mins read

Meri Beckwith

Co-CEO

Meri is a former life sciences and healthtech venture capital investor, with an MSc in Biology from the University of Oxford. Serving on the boards of health and biotech companies, he saw CROs repeatedly fail to deliver clinical trials on time and on budget. After participating in a COVID-19 vaccine trial, he saw how fragmented integrated technology, poor patient experience and operational problems at sites cascaded up to the cost and timeline overruns he experienced as an investor. He founded Lindus to fix these problems and provide a more accountable, predictable model for research.

We're excited to launch Off Protocol, a podcast that challenges the status quo of clinical trials and explores the realities of clinical research.

Hosted by Lindus Health co-CEO, Meri Beckwith, Off Protocol is an extension of our mission to show the world better ways of running clinical research. Through honest conversations with experts across the industry, we're creating a space to share real stories, confront challenges head-on, and explore lessons learned from the field.

Whether you're a sponsor, site coordinator, CRA, regulator, innovator, or simply curious about clinical research, Off Protocol offers the insights and perspectives you need to navigate the evolving landscape of clinical trials. This is our commitment to transparency, education, and advancing the conversation around what clinical research can and should be.

Ready to go off script? Listen to the first episode with our very own medical monitor, Dr. Anita Phung, “Why Women Are Not Just ‘Small Men’ in Clinical Trials,” on your preferred streaming platform:

‍

Listen on Spotify

Listen on Apple Podcasts

Listen on YouTube Podcasts

Listen on Amazon Music

This is some text inside of a div block.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

More from Lindus

General

03 Jun 2026

Articles

An AI pilot is only as good as the data pipeline underneath it: our response to the FDA on AI-enabled optimization of early-phase clinical trials

Lindus recently submitted a public comment to the FDA on the AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program (Docket No. FDA-2026-N-4390). We support the pilot and believe it can be designed to answer harder questions than the request for information currently sets up.

View

General

01 Jun 2026

Blog

Stop prototyping, start building: How AI is shaping product & design in 2026

At Lindus, we believe AI will empower our tech organization to build better products. LLMs are unlocking potential across product management, design, and engineering, in ways that would have seemed far-fetched even two years ago. But the way we work is changing fast, and we think it's worth sharing what that looks like in practice.

View

General

20 May 2026

Blog

What James Lind would ask us on Clinical Trials Day

What James Lind would ask us on Clinical Trials Day is whether the systems we have built are worthy of the participants, sites, investigators, and teams who make clinical research possible.We do not think they are yet, but we know they can be.

View

Diagnostic

11 Mar 2026

Blog

Achieving FDA-Grade Data Quality in Large-Scale Liquid Biopsy Screening Trials

"The data pipeline, from medical record retrieval to structured EDC output, has to be designed for regulatory scrutiny from the start. Retrofitting data quality into an operational model that wasn't built for it creates avoidable risk at exactly the wrong stage of a program."

View